Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
British Journal of Cancer

Publisher Rights Statement:
via europepmc

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients

L.A. Stark1, M.J. Arends1, K.M. McLaren1, E.C. Benton2, H. Shahidullah2, J.A.A. Hunter2 & C.C. Bird1

1Department of Pathology, Edinburgh University Medical School, Teviot Place, Edinburgh, UK; 2Department of Dermatology, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh, UK.

Summary: Renal allograft recipients suffer from a markedly increased susceptibility to premalignant and malignant cutaneous lesions. Although various aetiological factors have been implicated, little is known of the associated genetic events. In this study we initially employed immunocytochemical techniques to investigate the prevalence and localisation of accumulated p53 in over 200 cutaneous biopsies (including 56 squamous cell carcinomas) from renal allograft recipients and immunocompetent controls. In renal allograft recipients accumulated p53 was present in 24% of uninvolved skin samples. 14% of viral warts. 41% of premalignant keratoses. 63% of intraepidermal carcinomas and 56% of squamous cell carcinomas [squamous cell carcinoma and intraepidermal carcinoma differed significantly from uninvolved skin (P < 0.005) and viral warts (P < 0.01)]. A similar trend was revealed in immunocompetent patients (an older, chronically sun-exposed population) but with lower prevalence of p53 immunoreactivity: 25% of uninvolved skin samples. 9% of viral warts. 25% of keratoses. 53% of intraepidermal carcinomas and 53% of squamous cell carcinomas. These differences were not statistically significant. Morphologically, p53 immunoreactivity strongly associated with areas of epidermal dysplasia and the abundance of staining correlated positively with the severity of dysplasia. These data suggest that p53 plays a role in skin carcinogenesis and is associated with progression towards the invasive state. No correlation was observed between accumulated p53 and the presence of human papillomavirus (HPV): DNA in any of the lesions. Single-strand conformational polymorphism analysis (exons 5–8) was used to determine the frequency of mutated p53 in 28 malignancies with varying degrees of immunopositivity. p53 mutations were found in 5 9 (56%) malignancies with p53 staining in > 50% of cells, reducing to 1 6 (17%) where 10–50% of cells were positively stained and none where < 10% of cells were stained. These data imply that factors other than p53 gene mutation play a part in accumulation of p53 in skin cancers.

The p53 gene encodes a 53 kDa phosphoprotein that acts as a transcription factor and has tumour-suppressor functions. The wild-type gene product also has the ability to induce growth arrest and or apoptosis in response to DNA injury, preventing replication of genome that have suffered DNA damage (Kastan et al., 1991; Hartwell, 1992; Lane, 1992; 1993; Unger et al., 1992; Clark et al., 1993; Hall et al., 1993). Mutations in the p53 gene are considered to play a significant part in the development of many human malignancies: a high frequency of mutation is observed in most of the common forms of human cancer and there are elevated rates of malignancy in patients with Li–Fraumeni syndrome (in which there is an inherited p53 gene mutation) and in genetically engineered. p53-deficient mice (Baker et al., 1989; Negro et al., 1989; Srivastava et al., 1990; Hollstein et al., 1991; Donehower et al., 1992; Purdie et al., 1994). A number of oncogenic viral proteins can also form complexes with wild-type p53, initiating gene inactivation by mechanisms other than mutational loss of function (Scheffner et al., 1990; Yew & Berk, 1992; Debbas & White, 1993; Moran, 1993). Most of the mutations observed in p53 are thought to induce conformational changes in the protein product, increasing its half-life and rendering it detectable by immunocytochemical techniques (Milner & Cook, 1986; Gannon et al., 1990; Milner & Medcalf, 1991; Montenarh, 1992; Wynford-Thomas, 1992).

Renal allograft recipients (RARs) manifest a greatly increased susceptibility to cutaneous malignancy, with squamous cell carcinoma (SCC) occurring commonly, especially in patients with long graft life or high sun exposure (Shuttleworth et al., 1987; Alloub et al., 1989; Benton et al., 1992). These malignancies, however, form part of the wider spectrum of cutaneous disease observed in RARs that includes viral warts (VWs) and keratoses (Ks) displaying varying degrees of epidermal dysplasia and topographical continuity with intraepidermal carcinoma (IEC) and invasive SCC (Blessing et al., 1989; Benton et al., 1992). Although a number of putative aetiological factors have been implicated in the development of these malignancies, including ultraviolet (UV) radiation (Bloome & Larko, 1984; Boyle et al., 1984), decreased cell-mediated immunity (Streilein, 1991) and human papillomavirus (HPV) infection (Rudlinger et al., 1986; Barrett et al., 1989; Benton et al., 1992; Stark et al., 1994), little is known of the associated genetic events and whether these may differ in RARs and immunocompetent patients (ICPs). To our knowledge, there have been no major studies in which the role of p53 in the development of cutaneous lesions in RARs has been considered, although p53 mutations have been reported to occur in IECs and SCCs from ICPs (Brash et al., 1991; Gusterson et al., 1991; Pierceall et al., 1991; McGregor et al., 1992; Burns et al., 1993; Campbell et al., 1993a, b).

In this study we have employed immunocytochemical techniques to compare the prevalence of p53 accumulation in premalignant and malignant cutaneous lesions from both RARs and ICPs. Single-strand conformational polymorphism (SSCP) analysis was also employed to determine the relationship between positive immunocytochemistry and p53 gene mutations. The relationship between p53 expression and the HPV status of the lesions was also considered since it has been reported that viral oncoproteins may play a part in p53 inactivation in other HPV-associated malignancies (Scheffner et al., 1990, 1991, 1992; Werness et al., 1990; Crook et al., 1991, 1992).

Materials and methods

Patients

Sixty RARs (mean age 49 years, range 20–71 years) and 83 ICPs (mean age 68 years, range 12–94 years) were investigated. All SCCs came from 10 RARs and 17 ICPs. RARs

Correspondence: C.C. Bird, Department of Pathology, Edinburgh University Medical School, Teviot Place, Edinburgh.

Received 21 January 1994; and in revised form 16 May 1994.
received transplants between 1965 and 1992 (mean duration of transplant 10.8 years, range 1–26 years). Prior to 1984, prednisolone and azathioprine were the main immunosuppressive drugs used, but thereafter most patients received prednisolone and cyclosporin A. ICPs all presented to the Dermatology Department in Edinburgh Royal Infirmary for treatment of viral warts or skin tumours. Most of these patients were elderly with lesions on sun-exposed sites.

**Tissue collection**

One hundred and thirty-five and 68 cutaneous lesions were collected from RARs and ICPs respectively. These included 56 SCCs and 62 IECs. Six millimetre punch biopsies of normal (sun-exposed), forearm skin were also collected from 21 RARs and 12 ICPs. Biopsy samples were bisected longitudinally; half were placed immediately in PLPD (periodate-lysine-paraformaldehyde-dichromate) (Holgate et al., 1986), and 10% formalin and fixed for 24 h at 4°C before paraffin embedding. Histological assessment and immunohistochemistry were carried out on sections prepared from paraffin-embedded material. The other half were snap frozen in liquid nitrogen and stored at −70°C to await DNA extraction and virological investigation.

**DNA extraction and HPV detection**

Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM EDTA, 100 mM sodium chloride, 5 mM DTT, 1% SDS 1.5 mg/ml-1 proteinase K) then incubated at 37°C overnight. DNA extraction was carried out using a standard phenol–chloroform extraction technique (Sambrook et al., 1989). Two methods were employed to screen for the presence of HPV DNA (Stark et al., 1994). Southern analysis, using mixed HPV probes at low hybridisation (Tm=−40°C) and washing stringency (Tm=−35°C), was used to detect common cutaneous and epidermodysplasia verruciformis (EV)-related types. The polymerase chain reaction (PCR) was used to detect specific HPV types 1, 2, 5, 8, 6, 11, 16 and 18 (Arends et al., 1991; Stark et al., 1994).

**Histopathology**

The skin lesions were classified as follows: viral warts (VWs) exhibited symmetry, papilliferous architecture and koilocytic change; verrucous keratoses (VKs) displayed the architecture of warts but lacked definitive cytological features of viral infection; actinic keratoses (AKs) showed basal budding and basal hypermelanosis (degrees of dysplasia were assessed in both types of keratosis); intraepidermal carcinoma (IECs) showed either full-thickness dysplasia or severe dysplasia and acantholyis of the basal layer, invasive squamous cell carcinoma (SCC) showed dermal invasion (Blessing et al., 1989).

**Immunohistochemistry**

Immunohistochemistry was performed on 3 µm sections of PLPD- and formalin-fixed tissue using the mouse anti-p53 monoclonal antibodies MAb Do-7 (Vojtesek et al., 1992) and PAB 1801 (Banks et al., 1986) and a standard ABC horseradish peroxidase (HRP) technique (Dako, High Wycombe, Bucks, UK) as previously described (Purdie et al., 1991). Formalin-fixed tissue was treated with MAb Do-7 (1:100 dilution, overnight incubation) only, whereas PLPD-fixed material was treated with MAB Do-7 and PAB 1801 (1:100 dilution, 1 h incubation). Each section was scored by two independent observers and the extent of staining recorded on the following graded scale: 1 = <10%, 2 = 10–50% and 3 = >50% of cells in a lesion showing positive nuclear staining. Sections were recorded as positive when immune precipitate was visible in >10% of cells in the lesion, i.e. grades 2 and 3 only. Lesions with grade 1 score were considered to be negative. The histological localisation of accumulated p53 within each lesion was also noted.

**Single-strand conformational polymorphism (SSCP) analysis and direct DNA sequencing**

Twenty-eight tumour samples and 12 normal skin samples from RARs and ICPs underwent SSCP analysis. PCR was performed on 0.1–1 µg of genomic DNA using primers specific for p53 exons 5, 6, 7 and 8. SSCP analysis was based on the protocol of Cripps et al. (manuscript in preparation). The 100 µl PCR reaction was purified using a standard chloroform extraction technique. A 5–10 µl volume of the purified product was alkali denatured (80 µM sodium hydroxide, 10 µM EDTA, at 48°C for 5 min). 10 µl of stop solution added (10 µM EDTA, 0.1% bromophenol blue, 0.01% xylene cyanol) and the whole sample loaded onto a 5% glycerol, 0.5 × MDE Hydrolink gel. Following electrophoresis (25°C, 20 W, for 2–3 h) the DNA was visualised by silver staining (BioRad kit). SSCP mutations were detected as bands of altered mobility. In one sample showing an exon 7 mutation by SSCP analysis, sequencing was performed using the Sequenase (II) kit (United States Biochemical) with cloned double-stranded DNA.

**Results**

**Immunohistochemical demonstration of p53**

Experiments were initially carried out to determine the specificity and sensitivity of MAb Do-7 and PAB 1801 staining in PLPD- and formalin-fixed material. No statistically significant difference in the number of positive cases was detected in formalin- or PLPD-fixed material (data not shown), permitting results from both fixatives to be combined. In 74 lesions tested with both MAB Do-7 and PAB 1801 the number of positive cases was identical, and within each section both antibodies reacted with similarly located cells. Overall, MAB Do-7 gave a more intense precipitate than PAB 1801, although some minor variation in intensity occurred between assays.

**Accumulated p53 in cutaneous lesions from RARs and ICPs**

A total of 156 biopsies from RARs and 80 from ICPs were screened for the presence of accumulated p53 using MAB Do-7 (Table I, Figures 1 and 2). In both populations, over 50% of SCCs exhibited p53 immunoreactivity in >10% of cells (grades 2 and 3). Overall, the number of lesions exhibiting accumulated p53 and the grade of staining within these lesions correlated positively with the degree of dysplasia present. In RARs, significantly more IECs and SCCs demonstrated accumulated p53 than either uninvolved sun-exposed skin (US) (χ² test, P<0.05) or VWs (χ² test, P<0.01). A similar trend was revealed in ICPs, although a lower proportion of cases were stained positive for p53. However, the differences between SCCs or IECs and US in ICP were not statistically significant.

**Distribution of accumulated p53**

In both RARs and ICPs, immunostaining of lesions was confined to nuclei of dysplastic epithelial cells and was most

<table>
<thead>
<tr>
<th>Patients</th>
<th>US</th>
<th>VWs</th>
<th>Ks</th>
<th>IECs</th>
<th>SCCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>RARs</td>
<td>5</td>
<td>21</td>
<td>3</td>
<td>149</td>
<td>24</td>
</tr>
<tr>
<td>ICPs</td>
<td>3</td>
<td>12</td>
<td>25</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

*SSections in staining with >10% of nuclei in the lesion (grades 2 and 3) were scored as positive. RAR, renal allograft recipient; ICP, immunocompetent patient; VW, viral wart; K, verrucous and actinic keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma; US, uninvolved, sun-exposed skin. *P<0.05 using χ² test. **P<0.01 using χ² test.*
abundant in areas of severe dysplasia (Figure 2a). Within K and IEC lesions, staining was generally strongest in basal epithelial layers, particularly at sites of basal budding where dysplastic changes were most severe (Figure 2a and b). This was particularly notable in Ks exhibiting actinic features. In dysplastic Ks and IECs, acantholysis and suprabasal clefting were also observed to correlate with strong p53 staining. In tissue sections that contained skin appendages, the specialised lining cells were always negative and staining was confined to the surrounding dysplastic cells (Figure 2c). While the majority of SCCs showed accumulated p53, there was a tendency for greater positivity to occur in less-well-differentiated lesions (Figure 2d) and adjacent normal epidermis remained unstained. Occasionally, p53 was detected in dysplastic basal cells and overlying IECs but not in contiguous tongues of invasive carcinoma. The positive staining in non-lesional, sun-exposed skin was light in intensity and predominantly basal in location in cells exhibiting only mild dysplastic change.

**HPV status and presence of accumulated p53**

One hundred and twenty-six biopsies from RARs and 75 from ICPs were also screened for the presence of HPV DNA using low-stringency Southern hybridisation with a cocktail of HPV probes, and type-specific PCR for HPV types 1, 2, 5, 8, 6, 11, 16 and 18 (Table II). The details of these results are reported elsewhere (Stark et al., 1994). Overall, no relationship was observed between the presence of accumulated p53 and HPV DNA in premalignant or malignant cutaneous lesions from RARs or ICPs. The prevalences of the specific HPV types 1, 2, 5, 8, 6, 11, 16 and 18 were also too low to determine whether any correlation existed between these HPV types and p53 immunoreactivity.

### SSCP analysis of p53 immunopositive and immunonegative lesions

SSCP analysis of exons 5–8 of the p53 gene was performed on 28 IECs: SCCs from RARs and ICPs. Fifteen of these were immunopositive (grades 2 and 3) and 13 were immunonegative (including seven with grade 1 staining) (Table III and Figure 3). Overall, SSCP mutations (SSCPs) were detected in 6/28 (21%) malignancies [3/15 (20%) SCCs and 3/13 (23%) IECs]. However, the incidence of mutation was related to the grade of p53 positivity detected by immunocytochemistry with 5/9 (56%) grade 3, 1/6 (17%) grade 2 and no grade 1 lesions showing SSCP. Three of the SSCP were in exon 7 (all grade 3), two in exon 5 (one grade 3, the other grade 2) and one in exon 8 (grade 3). In our series, no SSCP were detected in immunonegative cancers or matched normal skin samples and there was no difference in the number of SSCP present in RARs and ICPs. Direct DNA sequencing of one SCC with a SSCP mutation in exon 7 revealed a C→T transition at codon 248 (Figure 3). SSCP were detected in

---

Figure 1: Extent of p53 staining in cutaneous lesions from RARs and ICPs. Grade 1 (■) = <10% of cells, grade 2 (▲) = 10–50% of cells, grade 3 (▲▲) = >50% of cells in a lesion showing positive nuclear staining by immunocytochemistry; neg (□) = negative by immunocytochemistry, US, uninvolved, sun-exposed skin; VW, viral wart; K, keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma.

Figure 2: Histological distribution of accumulated p53. a. Severely dysplastic keratosis (left) is associated with strong p53 immunostaining as compared with negative normal epidermis (right). b. p53 immunostaining is localised to the dysplastic basal cells in actinic keratosis. c. Dysplastic basal cells are positive for p53 while the specialised cells in appendages are negative. d. Nuclear localisation of p53 in an invasive squamous cell carcinoma from a RAR. p53 immunocytochemistry was performed using PAb Do-7 and a standard ABC horseradish peroxidase technique.
Table II  Correlation between presence of HPV DNA and accumulated p53 in cutaneous lesions from RARs and ICPs

<table>
<thead>
<tr>
<th>Patients</th>
<th>Histology</th>
<th> </th>
<th> </th>
<th> </th>
<th> </th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HPV+</td>
<td>HPV-</td>
<td>HPV+</td>
<td>HPV-</td>
<td></td>
</tr>
<tr>
<td>RARs</td>
<td>p53+</td>
<td>p53-</td>
<td>p53+</td>
<td>p53-</td>
<td></td>
</tr>
<tr>
<td>SCC</td>
<td>0.3</td>
<td>3.3</td>
<td>5.16</td>
<td>11.16</td>
<td>1.1</td>
</tr>
<tr>
<td></td>
<td>0.21</td>
<td>9.11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VWs</td>
<td>1.9</td>
<td>9.16</td>
<td>0.55</td>
<td>1.5</td>
<td>4.5</td>
</tr>
<tr>
<td></td>
<td>0.16</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KS</td>
<td>10.4</td>
<td>6.10</td>
<td>6.19</td>
<td>13.19</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>3.3</td>
<td>8.11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IECs</td>
<td>12.8</td>
<td>12.42</td>
<td>13.20</td>
<td>7.20</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>2.4</td>
<td>11.24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCCs</td>
<td>7.15</td>
<td>8.15</td>
<td>10.16</td>
<td>6.16</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>4.10</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*pSections with staining in >10% of nuclei in the lesion (grade 2 and 3) were scored as positive. RAR, renal allograft recipient; ICP, immunocompetent patient; US, uninvolved, sun-exposed skin; VW, viral wart; K, keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma.

Table III  SSCP analysis of immunopositive and immunonegative tumours from RARs and ICPs

<table>
<thead>
<tr>
<th>Patients</th>
<th>Histology</th>
<th>Neg</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>RARs</td>
<td>SCC</td>
<td>0.1</td>
<td>0.3</td>
<td>0.2</td>
<td>3.3</td>
</tr>
<tr>
<td>IEC</td>
<td>0.3</td>
<td>0.1</td>
<td>0.1</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0.5</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICPs</td>
<td>SCC</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>IEC</td>
<td>0.2</td>
<td>0.1</td>
<td>1.1</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0.5</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ICC, immunocytochemical; SSCP, p53 mutations as detected by SSCP analysis; grade 1: <10%, grade 2: 10–50%; grade 3: >50% of cells in a lesion showing positive nuclear staining; RAR, renal allograft recipient; ICP, immunocompetent patient; SCC, squamous cell carcinoma; IEC, intraepidermal carcinoma.

Figure 3  a. Examples of SSCP mutations in exons 5 and 7 of p53 in cutaneous malignancies from RARs and ICPs. Using SSCP analysis, a single base change, such as a point mutation, is visualised as a band of altered migration (as indicated by arrows) in a polyacrylamide gel. Samples 1 and 16 = squamous cell carcinomas from renal allograft recipients, both with grade 3 staining by immunocytochemistry (ICC); sample 36 = an intraepidermal carcinoma from an immunocompetent patient with grade 2 staining by ICC. b. Direct DNA sequencing of exon 7 from sample 1 showing a C–T transition at codon 248 of p53.

Discussion

p53 accumulation and progression in cutaneous carcinogenesis

In this study we have demonstrated the presence of accumulated p53 in over 50% of cutaneous SCCs from both RARs and ICPs suggesting that p53 may play a role in skin carcinogenesis in both populations. This detection level is in broad agreement with previously reported results for SCC in ICPs in which it has ranged from 15% to 56% of lesions (Gusterson et al., 1991; McGregor et al., 1992; Ro et al., 1992). A striking feature of our study was the increase in prevalence and extent of staining which occurred as lesions progressed through the histological spectrum of neoplasia. Indeed, there was a close correlation between the extent of staining in these lesions and the severity of dysplasia. These results strongly suggest that in skin carcinogenesis, in both RARs and ICPs, accumulation of p53 represents an important step in malignant progression. This hypothesis is supported by recent studies of skin carcinogenesis in p53 null mice, in which inactivation of p53 specifically associates with progression of benign papillomas to SCCs (Kemp et al., 1993). It is important to note, however, that the occurrence of p53 immunoreactivity does not always equate with acquisition of the malignant state since in ICPs accumulated p53 can be demonstrated in solar keratoses, of which only a small proportion progress to invasive carcinoma (Marks et al., 1986). Clearly, other genetic events must contribute to the development of invasive skin malignancies. In this context it is also of interest that we found a small number of SCCs showing p53 staining in superficial dysplastic epidermis and adjacent areas of IEC but not in contiguous tongues of invasive SCC. One possible explanation for this may be that gross chromosomal deletions, involving 17p, have occurred in more invasive malignant elements, abolishing all p53 gene expression.

HPV and p53 in cutaneous lesions from RARs and ICPs

E6 oncoproteins from HPV types 16 and 18 can bind to and induce rapid degradation of wild-type p53 (Scheffner et al., 1990; Werness et al., 1990). From observations in anogenital cancers it has been proposed that p53 inactivation occurs either by complexing of wild-type p53 with such viral oncoproteins or, in the absence of virus, by mutational loss of gene function (Crook et al., 1991, 1992; Scheffner et al., 1991, 1992). This concept, however, remains controversial, and other workers have failed to confirm these suggestions (Busby-Earle et al., 1993; Cooper et al., 1993). We have recently reported the prevalence of HPV in cutaneous lesions from RARs (Stark et al., 1994) and suggested that the mechanism by which HPV contributes to skin carcinogenesis may differ from that proposed for anogenital cancer. The present study confirms our previous findings in that we have failed to demonstrate any relationship between the presence or absence of HPV DNA and accumulated p53 in dysplastic or frankly malignant skin lesions from RARs or ICPs. Moreover, p53 mutations were detected by SSCP analysis in both HPV-positive and -negative malignancies. Recently, it has also been demonstrated that the E6 oncoprotein from skin-associated HPV type 8 does not bind to p53, unlike its HPV 16 or 18 equivalent (Steger & Pfister, 1992). Therefore, if HPV is involved in cutaneous carcinogenesis, it must be presumed to act by a different mechanism from that found in anogenital cancer.

p53 mutations in cutaneous carcinogenesis

In this study SSCP analysis was used to demonstrate mutations in the p53 gene. Although the precise sensitivity of this technique is presently unknown, a recent study in our laboratory involving human colorectal cancer, in which both SSCP analysis and direct sequencing were performed, indi-
cates that approximately 80% of p53 mutations can be detected by SSCP analysis (Cripps et al., manuscript in preparation). The detection of p53 mutations in 21% of SCCs in our series is in agreement with previous reports for cutaneous cancer (Pierceall et al., 1991; Ro et al., 1992; Campbell et al., 1993a, b). With one exception, these mutations occurred in exons 5 and 7, in keeping with the suggestion that these exons contain mutational hotspots for most human malignancies (Brash et al., 1991; Hollstein et al., 1991; Pierceall et al., 1991; Campbell et al., 1993a, Levine, 1993). Molecular analysis of p53 mutations has previously suggested that the pattern of nucleotide alterations may be tissue dependent and related to the type of mutagenic agent involved (Harris, 1991; Vogelstein & Kinzler, 1992). For instance, CC to TT double-base changes are almost exclusively associated with UV-induced DNA damage (Brash et al., 1991). It is of interest, therefore, that the SCC in our series that was sequenced was found to contain a C→T transition at the codon 248 mutational hotspot, implicating UV radiation in its genesis.

p53 immunocytochemical detection and gene mutations

Immunocytochemistry has been proposed as a rapid and simple means of identification of p53 gene mutations. In the majority of tumours, good correlation has been observed between the presence of immunocytochemically stable p53 and gene mutations determined by sequencing or other methods (Gannon et al., 1990; Iggó et al., 1990; Bodner et al., 1992). However, it is also recognised that immunocytochemically detectable levels of wild-type p53 may occur in response to DNA injury, and that some p53 mutations do not result in immunocytochemical demonstration of p53 protein (Bodner et al., 1992; Oliner et al., 1992; Wynford-Thomas, 1992; Hall et al., 1993. Lane, 1993). In this study, SSCP analysis of exons 5–8 detected mutations in 615 (40%) immunopositive malignancies, with most mutations occurring in tumours with the largest number of positive cells (grade 3 lesions). This indicates that immunocytochemical detection of p53 does not always signify the presence of p53 gene mutations in skin cancers, particularly where there are relatively few positive cells. While the possibility remains that mutations may have occurred in exons other than 5–8, our own experience and that of others studying other common cancers suggests that this is likely to account for only a small proportion of cases. This implies that additional factors may contribute to the accumulation of p53 during the development of at least some skin cancers. Recently, the product of the mdm-2 gene, which is overexpressed in osteosarcomas, has been shown to bind to and inactivate p53 (Momand et al., 1992; Oliner et al., 1992). It is possible that similar proteins may be present in transformed epidermal cells, complexing with wild-type p53 and rendering it detectable by immunocytochemical methods. The identity of such proteins and their role in the accumulation of p53 and subsequent development of skin cancer remains to be established.

References


